In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) was $15.81 for the day, down -4.93% from the previous closing price of $16.63. In other words, the price has decreased by -$4.93 from its previous closing price. On the day, 0.79 million shares were traded. CNTA stock price reached its highest trading level at $16.6246 during the session, while it also had its lowest trading level at $15.78.
Ratios:
Our analysis of CNTA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 9.25 and its Current Ratio is at 9.25. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.29.
On September 20, 2024, Morgan Stanley Upgraded its rating to Overweight which previously was Equal-Weight and also upped its target price recommendation from $11 to $26.
On September 19, 2024, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $33.B. Riley Securities initiated its Buy rating on September 19, 2024, with a $33 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 25 ’25 when Weinhoff Gregory M bought 10,000 shares for $16.53 per share.
SAHA SAURABH sold 55,000 shares of CNTA for $918,060 on Mar 20 ’25. The Chief Executive Officer now owns 276,017 shares after completing the transaction at $16.69 per share. On Mar 20 ’25, another insider, SAHA SAURABH, who serves as the Officer of the company, bought 55,000 shares for $16.35 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNTA now has a Market Capitalization of 2214854656 and an Enterprise Value of 1642837248. Its current Enterprise Value per Revenue stands at 239.725 whereas that against EBITDA is -10.185.
Stock Price History:
The Beta on a monthly basis for CNTA is 1.50, which has changed by 0.42432427 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, CNTA has reached a high of $19.09, while it has fallen to a 52-week low of $7.75. The 50-Day Moving Average of the stock is -4.00%, while the 200-Day Moving Average is calculated to be 8.49%.
Shares Statistics:
CNTA traded an average of 844.70K shares per day over the past three months and 1035530 shares per day over the past ten days. A total of 132.63M shares are outstanding, with a floating share count of 80.34M. Insiders hold about 39.43% of the company’s shares, while institutions hold 54.79% stake in the company. Shares short for CNTA as of 1740700800 were 5458260 with a Short Ratio of 6.46, compared to 1738281600 on 3050896. Therefore, it implies a Short% of Shares Outstanding of 5458260 and a Short% of Float of 5.08.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are keenly observing as 2.0 analysts analyze and rate the current performance of Centessa Pharmaceuticals plc ADR (CNTA) in the stock market.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.3 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$1.37 and -$1.6 for the fiscal current year, implying an average EPS of -$1.5. EPS for the following year is -$1.78, with 3.0 analysts recommending between -$1.7 and -$1.89.
